514 related articles for article (PubMed ID: 17573581)
1. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
Rossi J; Bayram M; Udelson JE; Lloyd-Jones D; Adams KF; Oconnor CM; Stough WG; Ouyang J; Shin DD; Orlandi C; Gheorghiade M
Acute Card Care; 2007; 9(2):82-6. PubMed ID: 17573581
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.
Filippatos G; Rossi J; Lloyd-Jones DM; Stough WG; Ouyang J; Shin DD; O'connor C; Adams KF; Orlandi C; Gheorghiade M
J Card Fail; 2007 Jun; 13(5):360-4. PubMed ID: 17602982
[TBL] [Abstract][Full Text] [Related]
4. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
Klein L; O'Connor CM; Leimberger JD; Gattis-Stough W; Piña IL; Felker GM; Adams KF; Califf RM; Gheorghiade M;
Circulation; 2005 May; 111(19):2454-60. PubMed ID: 15867182
[TBL] [Abstract][Full Text] [Related]
5. Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia.
Madan VD; Novak E; Rich MW
Circ Heart Fail; 2011 Sep; 4(5):637-43. PubMed ID: 21673193
[TBL] [Abstract][Full Text] [Related]
6. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
Gheorghiade M; Abraham WT; Albert NM; Gattis Stough W; Greenberg BH; O'Connor CM; She L; Yancy CW; Young J; Fonarow GC;
Eur Heart J; 2007 Apr; 28(8):980-8. PubMed ID: 17309900
[TBL] [Abstract][Full Text] [Related]
7. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction.
Rusinaru D; Buiciuc O; Leborgne L; Slama M; Massy Z; Tribouilloy C
Am J Cardiol; 2009 Feb; 103(3):405-10. PubMed ID: 19166698
[TBL] [Abstract][Full Text] [Related]
8. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
Gheorghiade M; Rossi JS; Cotts W; Shin DD; Hellkamp AS; Piña IL; Fonarow GC; DeMarco T; Pauly DF; Rogers J; DiSalvo TG; Butler J; Hare JM; Francis GS; Stough WG; O'Connor CM
Arch Intern Med; 2007 Oct; 167(18):1998-2005. PubMed ID: 17923601
[TBL] [Abstract][Full Text] [Related]
9. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
10. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
Cavalcante JL; Khan S; Gheorghiade M
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
12. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
[TBL] [Abstract][Full Text] [Related]
13. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
Klein L; Massie BM; Leimberger JD; O'Connor CM; Piña IL; Adams KF; Califf RM; Gheorghiade M;
Circ Heart Fail; 2008 May; 1(1):25-33. PubMed ID: 19808267
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.
Payvar S; Orlandi C; Stough WG; Elkayam U; Ouyang J; Casscells SW; Gheorghiade M;
Am J Cardiol; 2006 Dec; 98(11):1485-8. PubMed ID: 17126655
[TBL] [Abstract][Full Text] [Related]
15. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
17. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
Blair JE; Khan S; Konstam MA; Swedberg K; Zannad F; Burnett JC; Grinfeld L; Maggioni AP; Udelson JE; Zimmer CA; Ouyang J; Chen CF; Gheorghiade M;
Eur Heart J; 2009 Jul; 30(13):1666-73. PubMed ID: 19411662
[TBL] [Abstract][Full Text] [Related]
18. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
[TBL] [Abstract][Full Text] [Related]
19. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
